[Observation on the efficacy of Eustachian tube dilation hormone under the guidance of endoscope in the treatment of sudden deafness].

Abstract

Objective:To evaluate the efficacy of Eustachian tube dilation hormone under the guidance of otoscope in the treatment of patients with sudden deafness. Methods:One hundred and seventy-six patients（185 ears） with sudden deafness treated by otorhinolaryngology head and neck surgery in Shaanxi Provincial People s Hospital from January 2020 to December 2020 were selected. According to the inclusion and exclusion criteria, 176 patients（185 ears） were randomly divided into control group（n=86, 90 ears） and study group（n=90, 95 ears）. The control group was treated with intratympanic injection of methylprednisolone（methylprednisolone sodium succinate for injection）, and the study group was treated with tympanic tympanoplasty under otoendoscope. The pure tone hearing threshold, effective rate and the incidence of adverse reactions were compared between the two groups before and after treatment. Results:The total effective rate of the study group was 84.21%（80/95）, slightly lower than that of the control group（84.44%）, but there was no significant difference between the two groups. The hearing threshold of pure tone in the two groups was significantly higher than that before treatment, and the average improvement of hearing in the study group（25.47±6.29） dB was slightly lower than that in the control group（27.33±7.55） dB, but there was no significant difference between the two groups（P>0.05）. There was no significant difference in the incidence of mild adverse reactions between the two groups（P>0.05）. There were no serious adverse reactions. Conclusion:The total effective rate, hearing improvement level and adverse reaction rate of patients with sudden deafness treated with Eustachian tube tympanic dilatation hormone under endoscope are the same as that of tympanic hormone injection.